Lyra Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Lyra Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2019 to 2023.
  • Lyra Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$12.4M, a 26.1% increase year-over-year.
  • Lyra Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$101M, a 54.1% decline year-over-year.
  • Lyra Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$67.1M, a 19.2% decline from 2022.
  • Lyra Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$56.3M, a 29.1% decline from 2021.
  • Lyra Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$43.6M, a 96.4% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$67.1M -$10.8M -19.2% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-22
2022 -$56.3M -$12.7M -29.1% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-22
2021 -$43.6M -$21.4M -96.4% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-29
2020 -$22.2M -$5.69M -34.4% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-09
2019 -$16.5M Jan 1, 2019 Dec 31, 2019 10-K 2021-03-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.